HYTN, Trump "Cannabis Regulation Relaxation" Preemptive Response...Targeting Cannabis Pharmaceutical-Grade Market Capture

HYTN Innovations (HYTNF) is actively strengthening its board and expanding its global operations to proactively respond to regulatory changes in the U.S. This move is seen as aligning with the reclassification trend of federal cannabis regulations and aims to reinforce its position in the “pharmaceutical-grade cannabis” market.

Headquartered in Canada, HYTN Innovations announced on the 20th (local time) the appointment of Fabian Monaco to its board of directors. Monaco has extensive experience in venture capital, private equity, and capital markets, having grown Gage Growth to approximately $100 million in revenue and led a sale transaction valued at over $500 million. The company stated that “his expertise in capital markets and M&A will play a key role in future global expansion.”

Based on similar considerations, HYTN signed a 60-day contract with digital marketing firm MCS starting March 23, investing €100,000 (about 156 million KRW). The partnership involves a cash-only payment structure, with no equity issuance. This is interpreted as a strategic focus on brand awareness and building a “global pharmaceutical pipeline,” rather than short-term fundraising.

This move is driven by an executive order signed by President Trump in December last year, which directs the federal government to reclassify cannabis from Schedule I to Schedule III. If implemented, cannabis would no longer be considered a controlled substance but instead classified as a drug under FDA and DEA regulation, requiring manufacturing, distribution, and prescription processes to meet federal standards.

HYTN emphasizes that it has prepared the necessary infrastructure for this change. The company holds a Drug Establishment License (DEL) and a Cannabis Drug License (CDL) issued by Health Canada, and has obtained GMP certification applicable in the U.S. Additionally, by establishing export networks targeting the UK, Germany, and Australia, it is regarded as one of the few companies with “regulatory compliance.”

The CDL obtained in July 2025 marks a turning point for business transformation. It allows HYTN to officially perform the functions of a “pharmaceutical company,” including supporting clinical research, developing prescription drugs, and submitting licensing applications. The company is also working on EudraGMDP registration for the European market and simultaneously developing CDMO services for clinical-stage companies.

Market potential has already been validated. In 2024, CBD-based prescription drug Epidiolex achieved $972.4 million in revenue with an 88.2% gross margin. Industry experts believe that “once regulatory clarity is achieved for cannabis-derived medicines, high-profit structures will form.”

HYTN’s product competitiveness is rapidly improving. The company has signed its first GMP-certified vaporizer export contract for the UK and is establishing a raw material supply chain of 4,000 kg for the German market. Since Germany relaxed regulations in 2024, medical cannabis imports have increased to 20,000 kg per quarter, making it a “core demand market.”

The company is also advancing: developing vaporizer products in partnership with SNDL, conducting stability testing projects, and preparing for commercialization of ceramic coil vaporizers. Long-term stability data obtained for the UK, Germany, and Australia are viewed as critical factors in the drug approval process.

Additionally, the company has received export licenses exceeding 400 kg from the UK Home Office and Health Canada, clearly shifting from an entertainment cannabis business to a “non-sterile pharmaceutical manufacturer.” HYTN states that it “will adapt to global regulatory changes and establish a leading position in the pharmaceutical-grade cannabis market.”

Market analysts view HYTN’s strategy as a “regulation-driven growth model.” By going beyond simple production and pre-establishing quality and certification systems compliant with pharmaceutical standards, the company is poised to benefit first when U.S. regulations relax.